Payment overview · 2025
General Payments
$385.29
19 reported records · 14 companies
Healthcare provider profile · identity verified
Lyndsi Cress, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · LITTLE RIVER, SC · NPI 1629480751
Verified facts
What the public records show
CMS Open Payments records show Lyndsi Cress, D.O. received $385.29 in general payments during 2025 across 19 reported records.
Dexcom, Inc. accounted for 18.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Nurtec Odt, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $71.73 | 18.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.53 | 11.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $42.03 | 10.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.47 | 7.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.29 | 6.6% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $23.56 | 6.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.52 | 6.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.85 | 5.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $20.70 | 5.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.31 | 5.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.06 | 4.4% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $15.65 | 4.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.25 | 4.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.34 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $385.29 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $71.73 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $42.03 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.47 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 168 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 59 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 623 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 492 | 136 |
| Lisinopril | Lisinopril | 400 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 91 |
| Losartan Potassium | Losartan Potassium | 356 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 105 |
| Gabapentin | Gabapentin | 328 | 102 |
| Omeprazole | Omeprazole | 306 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 86 |
| Trazodone Hcl | Trazodone Hcl | 236 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 196 | 61 |
| Metformin Hcl | Metformin Hcl | 195 | 64 |
| Famotidine | Famotidine | 192 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 76 |
| Eliquis | Apixaban | 168 | 31 |
| Furosemide | Furosemide | 166 | 67 |
| Allopurinol | Allopurinol | 143 | 40 |
| Simvastatin | Simvastatin | 138 | 44 |
| Meloxicam | Meloxicam | 137 | 42 |
| Metformin Hcl Er | Metformin Hcl | 130 | 41 |
| Potassium Chloride | Potassium Chloride | 126 | 40 |
| Sertraline Hcl | Sertraline Hcl | 119 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 38 |
| Carvedilol | Carvedilol | 116 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 27 |
| Montelukast Sodium | Montelukast Sodium | 106 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 31 |
| Buspirone Hcl | Buspirone Hcl | 95 | 33 |
| Mounjaro | Tirzepatide | 95 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 91 | 29 |
| Jardiance | Empagliflozin | 83 | 17 |
| Ozempic | Semaglutide | 80 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 17 |
| Spironolactone | Spironolactone | 72 | 20 |
| Alprazolam | Alprazolam | 70 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 21 |
| Prednisone | Prednisone | 67 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 20 |
| Meclizine Hcl | Meclizine Hcl | 64 | 29 |
| Atenolol | Atenolol | 63 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Alendronate Sodium | Alendronate Sodium | 60 | 17 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 59 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Clonazepam | Clonazepam | 56 | suppressed |
| Ezetimibe | Ezetimibe | 55 | 20 |
| Glimepiride | Glimepiride | 54 | 18 |
| Tramadol Hcl | Tramadol Hcl | 54 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 24 |
| Rybelsus | Semaglutide | 53 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 13 |
| Celecoxib | Celecoxib | 47 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 16 |
| Ibuprofen | Ibuprofen | 46 | 18 |
| Mirtazapine | Mirtazapine | 46 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 40 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 18 |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Estradiol | Estradiol | 36 | 13 |
| Finasteride | Finasteride | 36 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Topiramate | Topiramate | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Sucralfate | Sucralfate | 34 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 25 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 30 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 27 |
| Irbesartan | Irbesartan | 30 | 11 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Ibu | Ibuprofen | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 12 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Nystatin | Nystatin | 25 | 21 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 23 |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 18 |
| Linzess | Linaclotide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 13 |
| Glipizide Er | Glipizide | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $385.29 · 19 records | Dexcom, Inc. | AIRSUPRA, APTIMA, CAPLYTA, Dexcom G6 Transmitter, ECC Solutions, ELIQUIS, FARXIGA, INJECTAFER, Kerendia, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, QUTENZA, REPATHA, Rybelsus, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, UBRELVY, WaveWriter Alpha Prime 16 | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error